Home Page | Florida Hospital Center for Thrombosis Research

Introducing the Florida Hospital Center for Thrombosis Research

Welcome to the Florida Hospital Center for Thrombosis Research. Originally formed in 1994, this unique facility combines advanced clinical testing services with cutting edge basic and clinical research in the areas of hemostasis and thrombosis. Our web site is designed to be a source of information for health care professionals, patients and their families.

Visit our Resources and Patient Information sections to find out more.

Our Mission

To provide high quality clinical laboratory testing for the patients and physicians of Florida Hospital and beyond; and to undertake research that is clinically focused, ethically appropriate and fiscally responsible.

Our Expertise

The scientists and technologists of the Center for Thrombosis Research have many years experience in the area of blood coagulation. Our Clinical Laboratory can provide esoteric diagnostic testing, core laboratory services and timely evaluations of instrumentation and reagent systems.

Our Projects

Our scientists are working on multiple projects in the field of hemostasis and thrombosis. In the area of cancer research, we have broad interests in the relationship of blood coagulation to cancer growth and spread, and understanding why cancer patients are more at risk of thrombosis.

Latest News

06-06-11 FHCTR scientists to present research results in Kytoto, Japan

Center for Thrombosis Research scientists will be presenting the results of three of their research projects at the upcoming (July) International Society for Thrombosis and Hemostasis meetings in Kyto, Japan. The frist of these studies reports on microparticle-associated Tissue Factor in an animal model of pancreatic cancer as a cause of systemic hypercoagulability. The second study suggests that patients receiving heparin flushes during chemotherapy may have sufficient circulating heparin to support platelet activation by bevicizumab.

10-25-10 FDA approves dabigatran for stroke prevention, embolism, in AF patients

The US FDA has approved dabigatran (Pradaxa) for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The drug will be available in two doses: 150 mg twice daily and, for a small subset with severe renal impairment, 75 mg twice daily. At last there is an oral anticoagulant that is at least as safe and effective as warfarin but is more consistent in its effects and does not require cumbersome anticoagulation monitoring or careful attention to diet.

10-21-10 Abstracts accepted for 2010 ASH Meeting

Researchers at the Florida Hospital Center for Thrombosis Research have had two abstracts accepted for presentation at the 52nd Annual Meeting of the American Society of Hematology. The meeting will be held in Orlando on December 4-7, 2010. The authors and titles of these abstracts are:

Meyer T, Robles-Carrillo L, Desai H, Hatfield M, Amaya M, Francis JL, and Amirkhosravi A. Comparison of Platelet-Activating Potential of Bevacizumab+VEGF and Aflibercept+VEGF Complexes.

Spath B, Amirkhosravi A, Davila M, Francis JL, Eifrig B, Bokemeyer C and Langer F.

see all

Florida Hospital Center for Thrombosis Research
2501 North Orange Avenue
Suite #786
Orlando, FL 32804

Phone: (407) 303-2440 (main office)
Phone: (407) 303-2449 (clinical lab)
Fax: (407) 303-2441

Request more information